US20110092548A1 - Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical - Google Patents

Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical Download PDF

Info

Publication number
US20110092548A1
US20110092548A1 US12/295,139 US29513906A US2011092548A1 US 20110092548 A1 US20110092548 A1 US 20110092548A1 US 29513906 A US29513906 A US 29513906A US 2011092548 A1 US2011092548 A1 US 2011092548A1
Authority
US
United States
Prior art keywords
cancer
disease
treatment
administered
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/295,139
Other languages
English (en)
Inventor
Takuro Minowada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20110092548A1 publication Critical patent/US20110092548A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to a method and a medicament for treating or preventing a disease. More particularly, the present invention relates to a method and a medicament for treating or preventing a disease using cognition of the cerebrum.
  • a structure of a brain is said to be most mysterious in this universe.
  • a human brain is classified into cerebrum and cerebellum. Simply speaking, cerebrum is apart which controls the psychiatric function, and cerebellum is a part which controls balance sense. When these two are compared, the weight of cerebellum is around 11% of a whole brain, and cerebrum accounts for a major part.
  • cerebrum When a longitudinal cross-section of a brain is observed, in the center, there are diencephalon, mesencephalon, and medulla oblongata, and medulla oblongata which is continuous with spinal cord.
  • a brain is protected with a triple membrane consisting of dura mater, arachnoid mater and pia mater in this order from the outside, and an about one cup of spinal fluid is filled between the arachnoid mater and the pia mater.
  • a wrinkle indicates a folding part. Two thirds of a surface area of a human brain is hidden in a groove of this wrinkle, and can not be seen from the outside. What can be said regarding a wrinkle is only that the relationship between a surface area when wrinkles of the brain is removed and a size of a container for a brain determines the number of wrinkles.
  • a nerve cell is not divided. Assuming that there are a total of 14 billion nerve cells, all of the 14 billion nerve cells seem to be necessary for the balance or stabilization in a skull bone.
  • Dr. Takeshi Yoro former professor of the Institute of Brain Research, the University of Tokyo
  • Dr. Takeshi Yoro former professor of the Institute of Brain Research, the University of Tokyo
  • Dr. Takeshi Yoro former professor of the Institute of Brain Research, the University of Tokyo
  • Dr. Takeshi Yoro former professor of the Institute of Brain Research, the University of Tokyo
  • Dr. Takeshi Yoro former professor of the Institute of Brain Research, the University of Tokyo
  • prickle-like materials are projected from a nerve cell.
  • nerve fiber Normally, there are a few tens of prickles, and only one long prickle among them is called nerve fiber. It is shaped like a connected Vienna sausages and has a bulging part at the end. This is called terminal button.
  • the button attaches to a adjacent or peripheral nerve cell. They are not fused into each other but merely lapped and adhered. The more binding formats there are, the better results occur, that is, a brain in which larger number of this network of nerve cells is generated more closely results in the wisdom.
  • Entanglement of the nerve cells grows frequently three months after birth. It is said that, at 15 months, the entanglement becomes more complicated and, at about 3 years old to 4 years old, the development of a fundamental network is completed. A size of a brain becomes about 4-fold bigger at around 4 year old than at birth, approximately the same size as an adult. For this reason, the environment in childhood is important.
  • Japanese psychiatric medicine is directed to psychiatric analytical methodology too much, and is substantially delayed in study involving the function and the structure of cerebrum or positioning of those psychiatric medicines in the clinic setting. From now on, such region must be studied more vigorously. Now, let's discuss on the function of a brain by exemplifying an easily understandable example.
  • initial therapy is important.
  • initial therapy which is naturally conducted in other departments, is not conducted in the department of psychiatry.
  • cerebrum function is greatly involved in a psychiatric disease, and a disorder of the cerebrum function is deeply involved therein, it is considered that a method to treat a psychiatric disease becomes clearer by checking the cerebrum function.
  • the concept is very simple. When an affected part comes out, it should be detected and suppressed as early as possible, and an intact part should be maintained so that the person can live a rosy later life. Of course, how to live depends on endeavor and device of each person.
  • cerebrum is deeply involved in a psychiatric disease, but in other physical diseases, the cerebrum function can not be neglected. It has been known also from clinical experience of the present inventor for more than 40 years that many diseases improve further by treatment on cerebrum together with local therapy.
  • the present inventor thinks that, regardless of the type of disease, the function of cerebrum integrating mind and body must be paid more attention to treat the disease. This is because, to say extremely, all information of a body is inputted in a brain. In addition, psychological matters including past, present, imagination and others are all together inputted into cerebrum. Furthermore, natural phenomenon during the years is memorized in a brain. Since cerebrum controls a body based on the natural phenomenon recognizing that safety is assured, the function of cerebrum has to be sufficiently maintained above all.
  • Cerebrum All information of a body is inputted in cerebrum. Cerebrum also has the function of cognizing abnormality when present anywhere. Cerebrum controls a whole body while maintaining safety of a body.
  • the present inventor has explained many actual cases where a cancer patient who received treatment of cerebrum using a tranquilizer showed a recovery tendency.
  • the present inventor itself suffered from large intestine cancer. After being discharged from hospital, the inventor has been on a tranquilizer and vitamin C. In a health check thereafter, proliferation and metastasis were not seen at all, and a cancer specialist was surprised at it.
  • the present inventor itself is a physician who experienced a major disease, and ardently felt the necessity of a reliable physician who performs “evidence-based medicine” like the present invention.
  • Non-Patent Literature 1 Terends Biotechnol. 2005 January; 23(1):34-41).
  • the Literature does not describe and suggest treatment of other diseases such as cancer utilizing the cognitive ability of a brain.
  • An object of the present invention is to develop a method of enhancing the cognitive ability of a brain to fundamentally cure a disease.
  • the present invention provides an evidence-based therapy ( FIG. 6 ).
  • the present invention provides the following:
  • a medicament for treating or preventing a disease comprising a combination of a major tranquilizer, and vitamin C or a salt thereof.
  • the major tranquilizer is selected from the group consisting of a butyrophenone derivative, a phenothiazine derivative and a benzamide derivative.
  • the major tranquilizer is a butyrophenone derivative, and the butyrophenone derivative is selected from the group consisting of haloperidol, spiperone and timiperone.
  • the medicament according to item 1, wherein the major tranquilizer is haloperidol.
  • the medicament according to item 1, wherein the major tranquilizer is administered at a half dose of treatment of a psychiatric disease.
  • the medicament according to item 1, wherein the drip infusion is a physiological buffer containing maltose.
  • the medicament according to item 1, wherein the drip infusion is an Ardofed injection solution.
  • the medicament according to item 10 wherein the antidepressant is administered when blood potassium is decreased.
  • the medicament according to item 10 contains fluvoxamine maleate.
  • the medicament according to item 10 is administered daily.
  • the medicament according to item 1 further combined with an iron agent.
  • the medicament according to item 12 wherein the iron agent comprises sodium ferrous citrate.
  • the medicament according to item 9 wherein the drip infusion is administered until appetite is worked up.
  • the medicament according to item 1, wherein the major tranquilizer is administered before bedtime.
  • the medicament according to item 1 further combined with drip infusion, an antidepressant and an iron agent.
  • the cancer is selected from large intestine cancer, colon cancer, rectum cancer, thyroid cancer, esophagus cancer, chorionic cancer, gallbladder cancer, neuroblastoma, maxillary cancer, oral cavity cancer, genitourinary cancer, malignant lymphoma, liver cancer, prostate cancer, lung cancer, lung cell cancer, breast cancer, stomach cancer, bladder cancer, pancreas cancer, testis cancer, uterus cancer, corpus uteri cancer, cervix uteri cancer, ovary cancer, pharynx cancer, myelocytic leukemia, brain edema, biliary cancer, neuroblasto tumor, melanocytoma, gastrinoma, insulinoma, carcinoid, kidney cancer, testicle cancer, adult T cell leukemia, vagina cancer, vulva cancer, skin cancer, upper airway cancer, head and neck cancer, teratoma, gallbladder cancer, acute myelocytic leukemia, acute lymph
  • a method for treating or preventing a disease including a step of administering a major tranquilizer, and vitamin C or a salt thereof to a subject suffering from the disease.
  • (31) Use of a combination of a major tranquilizer, vitamin C or a salt thereof in production of a medicament for treating or preventing a disease.
  • the use according to item 31, wherein the combination further comprises drops.
  • the present invention exerts such an effect that almost any diseases can be treated by a simple combination of two or more kinds of drugs which have previously been used.
  • the maximum treatment effect can be exerted while exhaustion of a physical strength of a patient is extremely suppressed, and an undesired side effect can be avoided.
  • FIG. 1 is a schematic view of a brain.
  • FIG. 2 is a schematic view in which structures of a brain are classified.
  • FIG. 3 is a schematic view illustrating a process in which a brain cognizes a disease.
  • FIG. 4 shows an example of disease therapy.
  • FIG. 5 is an illustration of evidence-based medicine.
  • FIG. 6 is an illustration of the Solution Focused Approach.
  • the “disease” which is a subject of the present invention may be any disease, and it can usually be a disease or a disorder which is associated with a disorder directly or indirectly associated with the immune state or homeostasis of a body.
  • a disease are not limited to, but include cancer, an infectious disease with viruses or bacterium, allergy, hypertension, hyperlipemia, diabetes, cardiac disease, brain infarction, dementia, obesity, arteriosclerotic disease, infertility, neuropsychiatric disease, cataract, progeria, and ultraviolet radiation hypersensitivity.
  • disorder which is a subject of the present invention can be an arbitrary disorder associated with abnormality of a body.
  • the disease or disorder can be a circulatory (blood cell or the like) disease or disorder.
  • a disease or disorder are not limited to, but include anemia (e.g. anaplastic anemia (particularly serious anaplastic anemia), renal anemia, cancerous anemia, secondly anemia, or refractory anemia), cancer or tumor (e.g.
  • anemia e.g. anaplastic anemia (particularly serious anaplastic anemia), renal anemia, cancerous anemia, secondly anemia, or refractory anemia
  • cancer or tumor e.g.
  • leukemia and hematopoietic failure after chemotherapy treatment thereof, thrombocytopenia, acute myelocytic leukemia, (particularly, first remission period (High-risk group), second remission period or remission periods thereafter) acute lymphatic leukemia (particularly, first remission period, second remission period or remission periods thereafter), chronic myelocytic leukemia (particularly, chronic period, transition period), malignant lymphoma (particularly, first remission period (High-risk group), second remission period or remission periods thereafter), and multiple myeloma (particularly, early stage after sideration).
  • acute myelocytic leukemia particularly, first remission period (High-risk group), second remission period or remission periods thereafter
  • acute lymphatic leukemia particularly, first remission period, second remission period or remission periods thereafter
  • chronic myelocytic leukemia particularly, chronic period, transition period
  • malignant lymphoma particularly, first remission period (High-risk group
  • the disease or disorder may be a nervous disease or disorder.
  • a nervous disease or disorder examples include dementia, stroke and sequela thereof, brain tumor, and spinal damage.
  • the disease or disorder may be an immune disease or disorder.
  • immune disease or disorder examples include the following: T cell deficiency, and leukemia.
  • examples of the disease or disorder may be a motor or skeletal disease or disorder.
  • examples of such a disease or disorder are not limited to, but include: bone fracture, osteoporosis, arthral bone dislocation, subluxation, ligament rupture, ligament damage, osteoarthritis, bone sarcoma, Ewing's sarcoma, osteogenesis imperfecta, and osteochondrodysplasia.
  • the disease or disorder may be a dermal disease or disorder.
  • a dermal disease or disorder examples include the following: atrichia, melanoma, skin malignant lymphoma, angiosarcoma, histiocytosis, bullosis, pustulosis, dermatitis, and eczema.
  • the disease or disorder may be an endocrine system disease or disorder.
  • a disease or disorder are not limited to, but include hypothalamus•pituitary gland disease, thyroid gland disease, accessory thyroid gland (parathyroid gland) disease, renal cortex medullae disease, saccharidoses, abnormal lipid metabolism, abnormal protein metabolism, abnormal nucleic acid metabolism, congenital abnormal metabolism (phenyl ketonuria, galactosemia, homocystinuria, maple syrup urine disease), analbuminemia, ascorbic acid synthesizing ability deficiency, hyperbilirubinemia, hyperbilirubinuria, kallikrein deficiency, mast cell deficiency, diabetes insipidus, vasopressin secretion abnormality, dwarfism, Wolman's disease (acid lipase deficiency), and mucopolysaccharidosis type VI.
  • the disease or disorder can be a respiratory disease or disorder.
  • a respiratory disease or disorder examples include the following: lung disease (e.g. pneumonia or lung cancer), and bronchial disease.
  • the disease or disorder can be an alimentary system disease or disorder.
  • a disease or disorder are not limited to, but include the following: esophagus disease (e.g. esophagus cancer), stomach•duodenum disease (e.g. stomach cancer or duodenum cancer), small intestine•large intestine disease (e.g. large intestine polyp, colon cancer or rectum cancer), biliary tract disease, liver disease (e.g.
  • cirrhosis hepatic hepatitis (type A, type B, type C, type D, type E or the like), fulminant hepatitis, chronic hepatitis, primary liver cancer, alcoholic liver disorder or drug liver disorder), pancreatic disease (acute pancreatitis, chronic pancreatitis, pancreas cancer, cystic pancreas disease), peritonea•abdominal wall•diaphragma disease (hernia or the like), and Hirschsprung's disease.
  • the disease or disorder can be a urinary disease or disorder.
  • a urinary disease or disorder examples include the following: kidney disease (renal failure, primary glomus disease, renal vascular disorder, convoluted tubule functional abnormality, interstitial renal disease, renal disorder due to systemic disease or kidney cancer), and bladder disease (inflammation of the bladder or bladder cancer).
  • the disease or disorder can be a reproductive system disease or disorder.
  • a reproductive system disease or disorder examples include the following: male reproductive disease (male infertility, prostate hypertrophy, prostate cancer or testis cancer), and female reproductive disease (female infertility, ovary functional disorder, fibroid, adenomyosis of the uterus, uterus cancer, endometriosis, ovary cancer or villosity disease).
  • the disease or disorder can be a circulatory disease or disorder.
  • a disease or disorder are not limited to, but include the following: heart failure, angina cordis, myocardial infarction, arrhythmia, valvular disease, cardiac muscle•capsula cordis disease, congenital cardiac disease (e.g. defect of the interatrial septum, interventricular septal defect, patent ductus arteriosus or tetralogy of Fallot), arterial disease (e.g. arteriosclerosis or aneurism), venous disease (e.g. varicosity), and lymph duct disease (e.g. lymphatic edema).
  • Examples of the disease or disorder curable by an immune system which can be treated or ameliorated by the present invention are not limited to, but include atopic dermatitis, and chronic arthritis rheumatoid.
  • Examples of the cancer which can be treated or ameliorated by the present invention are not limited to, but include brain tumor, leukemia, stomach cancer, lung cancer, liver cell cancer, metastatic cancer, primary breast cancer, recurrent breast cancer, primary liver cancer, biliary tract cancer, pancreas cancer, kidney cancer, prostate cancer, testis cancer, uterine corpus cancer, ovary cancer, lung small cell cancer, leukemia, biliary tract cancer, digestive system cancer, large intestine cancer, liver cancer, metastatic liver cancer, cervix uteri cancer, colon cancer, rectum cancer, thyroid cancer, breast cancer, urinary cancer, uterus cancer, esophagus cancer, cystic mole, chorionic cancer, ectopic HCG producing tumor, cholecystis cancer, bile duct cancer, neuroblastoma, maxillary cancer, oral cavity cancer, oral cavity bottom cancer, genitourinary cancer, thyroid cancer, malignant lymph (Hodgkin and non-Hodgkin), bladder cancer, hem
  • infectious disease examples include HBV infectious disease, HCV infectious disease, various bacterial infectious diseases, fungal infectious disease, viral infectious disease, HIV-1 infection, HIV-2 infection, herpesvirus (including HSV-1, HSV-2, CMV, VZV, HHV-6, HHV-7, and EBV without limitation) infection, adenovirus infection, poxvirus infection, human papilloma virus infection, hepatitis virus (e.g. including HAV, HBV, and HCV without limitation) infection, Helicobacter pylori infection, parasitic organism infection, and HTLV-1 infection.
  • HBV infectious disease HCV infectious disease
  • various bacterial infectious diseases including fungal infectious disease, viral infectious disease, HIV-1 infection, HIV-2 infection, herpesvirus (including HSV-1, HSV-2, CMV, VZV, HHV-6, HHV-7, and EBV without limitation) infection, adenovirus infection, poxvirus infection, human papilloma virus infection, hepatitis virus (e.g. including
  • Examples of the lifestyle disease which can be treated or ameliorated by the present invention are not limited to, but include diabetes, arteriosclerosis (including brain infarction, angina cordis, and myocardiac infarction without limitation), hypertension, malignant tumor, emphysema, and regressive change of bone.
  • arteriosclerosis including brain infarction, angina cordis, and myocardiac infarction without limitation
  • hypertension malignant tumor
  • emphysema emphysema
  • regressive change of bone regressive change of bone.
  • Examples of the parasite disease which can be treated or ameliorated by the present invention are not limited to, but include amebiasis, babesiasis, coccidiosis, cryptospolidiosis, prourine, external parasitic organism infectious disease, giardiasis, helminthiasis, leishmaniasis, Schistosoma infection, theileriasis, toxoplasmosis, trypanosomiasis, as well as Trichomonas infection and sporozoan (e.g.
  • intestine disease e.g. bloody flux, giardiasis
  • liver disease e.g. AIDS-associate
  • malaria e.g. AIDS-associate
  • Examples of the immune exacerbation which can be treated or ameliorated by the present invention are not limited to, but include allergic dermatitis and psoriasis.
  • immunodeficiency which can be treated or ameliorated by the present invention are not limited to, but include pyoderma, oral candidiasis, and virus infectious disease.
  • Examples of the drug poisoning which can be treated or ameliorated by the present invention are not limited to, but include alcoholic poisoning, nicotine poisoning, and heroin poisoning.
  • the “lifestyle disease” in the present specification refers to an arbitrary disease in which cause of a disease is gradually spread through repetition of a way of daily life or bad habit, and symptom comes out when the relevant person reaches a certain age.
  • Examples thereof include diabetes, hypertension, hyperlipemia, gout (hyperuricemia), obesity, arteriosclerosis, brain infarction, myocardiac infarction, pancreatitis, respiratory disease, stomach•duodenum ulcer, hepatic function disorder, osteoporosis, cancer, and periodontal disease
  • the lifestyle disease is a category according to a disease classifying method which puts a weight on cause as compared with the aforementioned sideration site. Since it is thought that in such a lifestyle disease, symptom is exacerbated due to reduction in the cognitive ability of a brain in any case, it is understood that the method of the present invention can act on any of these diseases.
  • the present invention can be useful in formulating an agent for preventing, ameliorating or treating central disease (e.g. apoplexia cerebri, apoplexia cerebri sequelae, delayed nerve cell death, Alzheimer's disease, dementia, eating disorder, Parkinson's disease, multiple sclerosis, or Creutzfeldt-Jakob disease), inflammatory disease (e.g. allergy, asthma or rheumatoid), circulatory disease (e.g. ischemic disorder, reperfusion disorder, hypertension, heart hypertrophy, angina cordis or arteriosclerosis), cancer (e.g.
  • central disease e.g. apoplexia cerebri, apoplexia cerebri sequelae, delayed nerve cell death, Alzheimer's disease, dementia, eating disorder, Parkinson's disease, multiple sclerosis, or Creutzfeldt-Jakob disease
  • inflammatory disease e.g. allergy, asthma or rheumatoid
  • circulatory disease e.g. ischemic disorder, reperfusion disorder, hypertension,
  • non-small cell lung cancer ovary cancer, prostate cancer, stomach cancer, bladder cancer, breast cancer, cervix uteri cancer, colon cancer or rectum cancer
  • metabolism disease e.g. diabetes, diabetic complication, obesity, arteriosclerosis, gout, cataract, hepatitis, amyloidosis or Wilson's disease
  • immune disease e.g. autoimmune disease
  • digestive organ disease e.g.
  • autoimmune disease chronic arthritis rheumatoid, multiple sclerosis or systemic erythematodes
  • degenerative disease amyloidosis, hemosiderosis or Wilson's disease
  • ischemic nerve cell damage apoplexia cerebri, apoplexia cerebri sequelae or delayed nerve cell death
  • ischemic•reperfusion damage cystic fibrosis, malignant tumor, infectious disease (multi organ failure due to sepsis or acute respiratory distress syndrome), liver failure, kidney failure, drug poisoning, heavy metal poisoning, radiation damage, ultraviolet damage (damage of skin, or lens or retina of eye due to ultraviolet-ray), other living body invasion (damage of skin or tissue due to heat or acid), viral disease (type B hepatitis, type C hepatitis, type D hepatitis, type E hepatitis, acquired immunodefici
  • type B hepatitis type C hepatitis
  • acquired immunodeficiency syndrome AIDS
  • diabetes diabetic complication
  • prostate hypertrophy gout
  • hepatitis autoimmune disease
  • malignant lymphoma pancreas cancer
  • cervix uteri cancer oral cavity bottom cancer
  • kidney cancer hypertension
  • ulcerous colitis chronic arthritis rheumatoid
  • chronic granulomatosis inflammatory bowl disease
  • neutropenia and neutrophilia as well as other disease, for example, substantially arbitrary cancer, viral disease, metabolism disease, circulatory disease, digestive organ disease, inflammatory disease, central disease, immune disease, infectious disease and lifestyle disease seem to be cured.
  • the present invention by increasing the disease cognitive ability of a brain, it was revealed that an arbitrary disease can be cured. In principle, since a brain can cognize any disease, it is to be understood that the present invention is effective for an arbitrary disease.
  • intracratal or “in vivo” refers to the inside of a living body. In a particular context, “intravital” refers to a position at which an objective tissue or organ is to be disposed.
  • the “subject” refers to an organism to which treatment of the present invention is applied, and is also called a “patient”.
  • the patient or the subject can be preferably a human.
  • a drug e.g. anticancer agent
  • a drug can be an arbitrary drug known in the art and, for example, such a drug can be an arbitrary drug (e.g. anti-cancer agent or antibiotic) known in pharmacy.
  • a drug can be two or more kinds of other drugs.
  • the drug can be administered at the same time with or at a different time from thermotherapy. Examples of such a drug include drugs listed in Japanese Pharmacopoeia latest edition, US Pharmacopeia latest edition, or latest edition of Pharmacopoeia in other countries.
  • the “major tranquilizer” is one of psycholeptics (generic name of a drug which suppressively acts on psychiatric function or emotion, and gives little change to other central nervous function) and, among them, refers to a drug by which anxiety or tension is relieved, and conscious disorder or sleeping does not occur at a normal dose.
  • a minor tranquilizer is used for the purpose of treating sleeping induction or anti-epilepsia, in addition to treating anxiety, agrypnia, or nervous disease with a drug). This is also called neuroplegica or antipsychotic drug.
  • Reserpine component of Indian snakeroot
  • chlorpromazine haloperidol, and lithium carbonate belong to this.
  • Examples of the major tranquillizer which is representatively used include a butyrophenone derivative (e.g. haloperidol, spiperone or timiperone), a phenothiazine derivative (fluphenazine maleate, trifluoperazine maleate, perphenazine, or prochlorperazine), a benzamide derivative (nemonapride or the like) an atypical antipsychotic drug (risperidone or the like) and the like.
  • a butyrophenone derivative e.g. haloperidol, spiperone or timiperone
  • a phenothiazine derivative fluphenazine maleate, trifluoperazine maleate, perphenazine, or prochlorperazine
  • a benzamide derivative nemonapride or the like
  • an atypical antipsychotic drug prisperidone or the like
  • an “amount” or a “dose” for the “psychiatric disease treatment” can be set based on Pharmacopoeia or a minimum amount which is normally used.
  • haloperidol at an initial stage, an amount is started with 0.75 to 2.25 mg a day, and gradually increased, and since a maintenance amount is 3 to 6 mg a day, and a maximum amount per day is 40 mg, 0.75 mg is adopted as a standard amount.
  • For spiperone in the first week, an amount is started with 0.45 to 1.5 mg, and since 1.5 to 4.5 mg a day is used thereafter, 0.45 mg is adopted as a standard amount.
  • timiperone at an initial stage, an amount is started with 0.5 to 3 mg a day, and since an amount is gradually increased to 3 to 12 mg a day thereafter, 0.5 mg is adopted as a standard amount.
  • vitamin C is a colorless crystalline substance (C 6 H 8 O 6 , molecular weight 176.13), a melting point is 190 to 192° C., and an L body of ascorbic acid is vitamin C.
  • a D body does not have that efficacy. It exhibits acidity in an aqueous solution because one of enol-form hydroxy groups is dissociated, and it makes a water-soluble neutral monoalkali salt. It is thought that it is involved in an oxidation reduction system, and exhibits the activity as a vitamin in a living body. It is present in adrenal gland at a particularly large amount in an animal body, and is contained also in the liver, pituitary gland, corpus luteum, and thymus at a large amount.
  • Ascorbic acid functions in hydroxylation of proline and lysine in collagen biosynthesis, metabolism of tyrosine and biosynthesis of catecholamine, detoxication of a living body foreign matter, suppression of production of nitrosoamine, hydroxylation of cholesterol into 7 ⁇ -cholesterol, absorption of iron, reduction of cytochrome c, activation of NADH reductase, metabolism of copper, and immune activation.
  • Ascorbic acid deficiency (vitamin deficiency) is mainly involved in deficiency of collagen biosynthesis, and is characterized in bleeding tendency such as scorbutus.
  • L-gulono- ⁇ -lactone is produced from D-glucose via L-glucuronic acid and L-gulonic acid and, further, L-gulono- ⁇ -lactone oxidase acts thereon to produce ascorbic acid.
  • Primate including a human, an elephant, a guinea pig, a certain bird, a bat, and fish is genetically deficient in L-guluno- ⁇ -lactone oxidase which catalyzes a final stage, and can not bio-synthesize ascorbic acid.
  • Ascorbic acid is required at a largest amount among vitamins, a necessary amount a day for an adult is about 50 mg, and a minimum necessary amount is 6.5 mg.
  • a method of utilizing reduction of an indophenol dye, 2,4-dichlorophenol indophenol is most frequently used. In the present invention, it is preferable to administer an artifact of vitamin C.
  • the “drip infusion” refers to drip infusion of a physiological buffer with or without specified components.
  • any substance may be used as the drip infusion as far as it is a physiological buffer which prevents elevation of a body temperature.
  • Representative examples include a physiological buffer containing maltose.
  • the “physiological buffer” refers to an arbitrary buffer which can be physiologically adapted.
  • a physiological buffer include a physiological saline (sodium chloride solution prepared so as to be isotonic with a body fluid component (particularly, serum), normally 0.9% NaCl: also called normal saline (a name of US Pharmacopoeia regarding a sodium chloride sterile aqueous solution isotonic with a body fluid)), a physiological salt solution (a mixed solution of salts used as a medium solution which makes isolated organs or tissues retain the normal function over a long term; a cation component of a solution is mainly Na + , and K + , Ca 2+ and Mg 2+ are added thereto and, further, a buffer such as sodium bicarbonate NaHCO 3 and sodium dihydrogen phosphate NaH 2 PO 4 are added to adjust a pH; glucose as an energy source is added in some cases), a Japanese Pharmacopoeia physiological saline, a Japanese Pharmacosaline,
  • the “antidepressant drug” or the “antidepressive drug” refers to a medicament which relieves oppression by enhancing the central activity of sympathetic nerve. Examples thereof include imipramine and tranylcypromine.
  • blood potassium when blood potassium is decreased, it is administered. Specifically, it is preferable that fluvoxamine maleate is administered.
  • iron agent is a drug containing iron as an ingredient, and serves for the purpose of increasing blood.
  • examples thereof include iron lactate, an iron iodide syrup, iron citrate, and iron sulfate.
  • iron lactate an iron iodide syrup
  • iron citrate an iron iodide syrup
  • iron citrate an iron iodide syrup
  • iron citrate an iron iodide syrup
  • iron citrate an iron iodide syrup
  • iron citrate iron sulfate
  • sodium ferrous citrate is used, being not limiting.
  • a medicament prepared with the factor of the present invention can be provided in an arbitrary preparation form as far as it is a form suitable for introduction into an organism.
  • a preparation form include solutions, injectables, and sustained release agents.
  • an administration method include oral administration, parenteral administration (e.g. intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, mucosal administration, rectal administration, vaginal administration, local administration to an affected part, or dermal administration), and direct administration to an affected part.
  • parenteral administration e.g. intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, mucosal administration, rectal administration, vaginal administration, local administration to an affected part, or dermal administration
  • direct administration to an affected part A form of delivery to a brain is preferable.
  • Formulations for such administration can be provided in an arbitrary preparation form. Examples of such a preparation form include solutions, injectables, and sustained release agents.
  • composition and the medicament of the present invention when administered systemically, can be a form of an aqueous solution which does not contain pyrogen, and can be received orally.
  • Preparation of such a pharmaceutically acceptable protein solution is within the technical range of a person skilled in the art, provided that considerable attention is paid to pH, isotonicity and safety.
  • injectables can be prepared by the method which is well-known in the art. For example, after being dissolved in a suitable solvent (physiological saline, buffer such as PBS or sterilized water), injectables can be prepared by filtration sterilization with a filter and, then filling in a sterilized container (e.g. ampoule or the like).
  • a suitable solvent physiological saline, buffer such as PBS or sterilized water
  • injectables can be prepared by filtration sterilization with a filter and, then filling in a sterilized container (e.g. ampoule or the like).
  • the injectables may contain a conventional pharmaceutical carrier if necessary.
  • a non-invasive administration method using a catheter can also be used.
  • the medicament of the present invention can be provided in a sustained release form.
  • a dosage form in the sustained release form can be any form known in the art as far as it can be used in the present invention.
  • Such a form can be, for example, a rod-like (pellet-like, cylinder-like, or needle-like) form, a tablet form, a disk-like form, a spherical form, or a sheet-like form.
  • a method of preparing the sustained-release form is known in the art, and is described, for example, in Japanese Pharmacopoeia, US Pharmacopoeia, and Pharmacopoeia in other countries, and examples of the method of preparing the sustained-release agent (sustaining administration agent) include a method utilizing dissociation of a drug from a complex, a method of preparing an aqueous suspension injection solution, a method of preparing an oily injection solution or an oily suspension injection solution, and a method of preparing an emulsion injection solution (o/w-type or w/o-type emulsion injection solution).
  • composition or the kit of the present invention can also contain a material compatible with a living body.
  • This material compatible with a living body can contain at least one member selected from the group consisting of silicone, collagen, gelatin, a copolymer of glycolic acid and lactic acid, an ethylene-vinyl acetate copolymer, polyurethane, polyethylene, polytetrafluoroethylene, polypropylene, polyacrylate and polymethacrylate. Silicone is preferable because of easy molding.
  • the biodegradable polymer include collagen, gelatin, a polymer or a copolymer synthesized by catalyst-free dehydration polycondensation from one or more kinds of members selected from the group consisting of ⁇ -hydroxycarboxylic acids (e.g.
  • glycolic acid lactic acid, and hydroxybutyric acid
  • hydroxydicarboxylic acids e.g. malic acid
  • hydroxytricarboxylic acids e.g. citric acid
  • poly- ⁇ -cyanoacrylic acid ester polyamino acid (e.g. poly- ⁇ -benzyl-L-glutamic acid)
  • polyacid anhydride such as a maleic anhydride-based copolymer (e.g. styrene-maleic acid copolymer).
  • a form of polymerization may be any of random, block and graft and, when ⁇ -hydroxycarboxylic acids, hydroxydicarboxylic acids, or hydroxytricarboxylic acids have an optically-active centre in a molecule, any of a D-body, an L-body, and a DL-body can be used.
  • a copolymer of glycolic acid•lactic acid can be used.
  • the “instruction” describes explanation of a method of administering the medicament of the present invention to a person who performs administration such as a physician, or a patient.
  • This instruction describes statement of instructing administration of the medicament of the present invention.
  • statement of instructing administration e.g. via injection
  • a skeletal muscle as an administration site may be described in the instruction.
  • This instruction is produced according to a format prescribed by a regulatory agency (e.g. Ministry of Health, Labor and Welfare in Japan, or Food and Drug Administration (FDA) in USA) in a country where the present invention is implemented, and there is described to the effect that the instruction was approved by the regulatory agency.
  • the instruction is a so-called package insert and is usually provided by a paper medium, being not limiting.
  • the instruction can be provided by a form of an electronic medium (e.g. homepage provided on the Internet or electronic mail).
  • the frequency at which the composition of the present invention is given to a subject can be easily determined by a person skilled in the art, in view of the use object, and the age, size, sex, medical history, and a treatment process of a subject. Examples of the frequency include administration once to several times a day, and daily to once per several months (e.g. once a week to once a month). It is preferable that administration once a week to once a month is performed while following-up the course.
  • An amount of the composition, the compound or the medicament used in the method of the present invention can be easily determined by a person skilled in the art, in view of the use object, and the age, size, sex and medical history of a subject, a form or a kind of a polypeptide, a nucleic acid, a composition, a medicament, and a form or a kind of a cell.
  • the “subject” refers to an organism to which treatment of the present invention is applied, and also to a “patient”.
  • the patient or the subject can be preferably a human.
  • a solvent used for formulation of a medicament in the present invention can have either of an aqueous or non-aqueous nature.
  • its vehicle can contain other formulation materials for altering or maintaining a pH, osmolarity, viscosity, cleanness, color, sterilizing property, stability, isotonicity, disintegrating rate, or odor.
  • the composition of the present invention can contain other formulation materials for altering or maintaining a release rate of an active ingredient, or promoting absorption or permeation of an active ingredient.
  • the present invention when formulated as a medicament or a pharmaceutical composition, can be prepared for storage in a form of a lyophilized cake or an aqueous solution, by mixing, if necessary, a physiologically acceptable carrier, an excipient or a stabilizer ((Remington's Pharmaceutical Sciences, 18th Edition, A. R. Gennaro, ed., Mack Publishing Company, 1990), and a selected composition having a purity to a desired degree.
  • a physiologically acceptable carrier an excipient or a stabilizer
  • an active ingredient e.g. polypeptide or nucleic acid
  • an active ingredient can be administered in a form of a composition together with one or more physiologically acceptable carriers, excipients, or diluents.
  • the suitable vehicle can be water for injection, a physiological solution, or an artificial brain spinal liquid, and other substances which are general to a composition for parenteral administration can be supplemented to them.
  • acceptable carriers, excipients or stabilizers are non-toxic to a recipient, and preferably inert at an administration amount and a concentration used, and examples thereof include the following: phosphate, citrate, other organic acids; antioxidant (e.g. ascorbic acid); low molecular weight polypeptide; protein (e.g. serum albumin, gelatin, or immunoglobulin); hydrophilic polymer (e.g. polyvinylpyrrolidone); amino acid (e.g.
  • glycine glutamine, asparagine, arginine or lysine
  • monosaccharide, disaccharide and other carbohydrates including glucose, mannose, maltose or dextrin
  • chelating agent e.g. EDTA
  • sugar alcohol e.g. mannitol or sorbitol
  • salt forming counterion e.g. sodium
  • nonionic surface active agent e.g. Tween, pluronic or polyethylene glycol (PEG)
  • the injectable can be prepared by a method well-known in the art.
  • the injectable can be prepared by dissolving an ingredient in a suitable solvent (physiological saline, buffer such as PBS, or sterilized water), filtration-sterilizing this with a filter and, then, filling this into a sterile container (e.g. ampoule).
  • a suitable solvent physiological saline, buffer such as PBS, or sterilized water
  • This injectable may contain a conventional pharmaceutical carrier, if necessary.
  • An administration method using a non-invasive catheter can also be used.
  • the suitable carrier include a neutral buffered physiological saline, and a physiological saline mixed with serum albumin.
  • the medicament of the present invention can be formulated as a lyophilized agent using a suitable excipient (e.g. sucrose).
  • compositions contains a Tris buffer at a pH of 7.0 to 8.5, or an acetate buffer at a pH of 4.0 to 5.5, and these can further contain sorbitol or a suitable substitute therefor.
  • a pH of the solution should be selected based on the relative solubility of an active ingredient of the present invention, at various pHs.
  • a procedure of formulating the preparation of the present invention is known in the art, and is described, for example, in Japanese Pharmacopoeia, US Pharmacopoeia, or Pharmacopoeia in other countries. Therefore, as far as there is the description of the present specification, a person skilled in the art can determine an amount or frequency of a medicament to be administered, without undue experiment.
  • a drug in another embodiment, in the present invention, it is planned to further administer other drugs.
  • a drug can be an arbitrary drug known in the art and, for example, such a drug can be an arbitrary drug known in pharmacy (e.g. antibiotic).
  • a drug can be two or more kinds of other drugs. Examples of such a drug include drugs listed, for example, in Japanese Pharmacopoeia latest edition, US Pharmacopoeia latest edition, or latest edition of Pharmacopoeia in other countries.
  • a disease which is a subject of the present invention is cancer.
  • the “cancer” refers to a general malignant tumor.
  • solid cancer refers to cancer having a solid shape, and is a concept contrary to hematopoietic tumor such as leukemia.
  • solid cancer are not limited to, but include breast cancer, liver cancer, stomach cancer, lung cancer, head and neck cancer, cervix uteri cancer, prostate cancer, retinoblastoma, malignant lymphoma, esophagus cancer, brain tumor, and bone tumor.
  • a basis of treatment of the present invention can be performed roughly at two stages. (1) If necessary, a body is cooled by drip infusion and, if necessary, two kinds of antibiotics are given. (2) If necessary, by cooling a brain by drip infusion, safety of a healthy part, which is 97% of a brain, can be maintained. Since a brain is altered in nature at 38.5° C. or higher, this is prevented to certainly leave a healthy part. If a brain can be cooled, a procedure other than drip infusion can be used. In addition, 60 to 80 thousand brain cells are dying a day. In addition, there can be bacterial infection in a urinary tract or lung of a patient.
  • a combination of vitamin C and a major tranquilizer (strong tranquilizer) of the present invention is ingested.
  • Vitamin C is ingested usually at 3 grams (capacity: 600 mg) in a tablet, or normally at 9 grams (capacity: 1800 mg) which is well enough.
  • Vitamin C used in treatment in a preferable embodiment is slightly different from natural vitamin C in a structure, because this is far more effective.
  • the present invention provides a medicament for treating or preventing a disease, including a combination of a major tranquilizer, and vitamin C or a salt thereof.
  • the present invention provides a method for treating or preventing a disease, including a step of administering a major tranquilizer, and vitamin C or a salt thereof to a subject suffering from the disease.
  • the major tranquilizer used in the medicament of the present invention can be a butyrophenone derivative, a phenothiazine derivative, or a benzamide derivative.
  • the butyrophenone derivative used in the present invention as a major tranquilizer can be haloperidol, spiperone or timiperone, preferably haloperidol.
  • the major tranquilizer to be administered is preferably administered at an amount which is half dose of an amount of psychiatric disease treatment, being not limiting.
  • a dose of a major tranquilizer administered in the present invention can be a daily dose of 0.25 mg to 1 mg in terms of haloperidol. It has been found out in the present invention that, by using a dose smaller than an amount used in a psychiatric disease, the cognitive ability of a brain can be enhanced.
  • the major tranquilizer is administered before bedtime, being not limiting.
  • Vitamin C used in the present invention can be ascorbic acid which is an artifact. This is because it has been empirically found out that the artifact is a several-fold to a several thousands-fold better in the effect than vitamin C which is a natural substance.
  • vitamin C in the medicament of the present invention, is contained so that a daily dose of 600 mg to 1800 mg as an effective amount is administered, being not limiting.
  • vitamin C may be further combined with pantothenic acid or a salt thereof, and this is not necessarily essential.
  • a physiological buffer supplying energy is preferable.
  • glucose or maltose can be utilized.
  • Maltose is preferable. This is because maltose can supply energy which is about 2-fold energy of glucose at the same osmotic pressure.
  • any buffer can be used as far as it is physiologically compatible. Examples of the physiological buffer containing maltose include an Aldofed injection solution. In an embodiment, this drip infusion is administered until appetite is worked up.
  • the medicament of the present invention can be characterized in that an antidepressant is combined.
  • the antidepressant can be administered when blood potassium is decreased.
  • examples of such an antidepressant include fluvoxamine maleate.
  • the antidepressant to be administered in the present invention is preferably administered daily, or may be administered arbitrarily.
  • the medicament of the present invention can be characterized in that an iron agent is combined.
  • the iron agent can include sodium ferrous citrate, but other iron agents may also be used.
  • the combinatorial medicament of the present invention may be a combination of drip infusion and an anti-depressant, in addition to a combination of the major tranquilizer and vitamin C.
  • the aforementioned arbitrary preferable effect is exerted.
  • a combinatorial medicament of the present invention may be further combined with drip infusion and an iron agent, in addition to a combination of the major tranquilizer and vitamin C. Also in this case, the arbitrary preferable effect described above in the present specification is exerted.
  • a combinatorial medicament of the present invention may be further combined with drip infusion, an antidepressant and an iron agent, in addition to a combination of the major tranquilizer and vitamin C. Also in this case, the arbitrary preferable effect described above in the present specification is exerted.
  • the disease which is a subject of the present invention can be an arbitrary disease and, particularly, is remarkably characterized in that at least one disease (e.g. cancer, muscular dystrophy and Huntington's chorea) is included.
  • the cancer which is a subject of the present invention can be large intestine cancer, colon cancer, rectum cancer, thyroid gland cancer, esophagus cancer, chorionic cancer, gallbladder cancer, neuroblastoma, maxillary cancer, oral cavity cancer, genitourinary cancer, malignant lymphoma, liver cancer, prostate cancer, lung cancer, lung cell cancer, breast cancer, stomach cancer, bladder cancer, pancreas cancer, testicle cancer, uterus cancer, uterine corpus cancer, cervix uteri cancer, ovary cancer, pharyngeal cancer, myelocystic leukemia, brain tumor, biliary tract cancer, neuroblast tumor, melanocytoma, gastrinoma, insulinoma, carcinoid, kidney cancer, test
  • a psychiatric disease such as dementia
  • a psychiatric disease such as dementia
  • the remarkable effect of the present invention should be recognized in that, even at a dose which was not previously thought to be a treatment dose, a surprising curing effect can be exerted by joint use of vitamin C.
  • cancer markers tumor markers
  • Mr. TM (76 year old) suffering from transverse colon cancer was treated as follows, and course of transverse colon cancer was observed.
  • the body weight at treatment initiation was 62 kg.
  • a Celanese (haloperidol) 0.75 mg tablet was administered before bedtime at 1 ⁇ 2 tablet a day.
  • CPG containing 1200 mg of ascorbic acid, and 18 mg of calcium pantothenate
  • an Aldofed injection solution maltose, potassium chloride, magnesium chloride, potassium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, magnesium chloride (hexahydrate), anhydrous sodium acetate, maltose (monohydrate) was infused at decreased appetite.
  • SSR1 Livox (fluvoxamine maleate, 25 mg) two tablets) was administered.
  • CEA 2.7 (standard value is 5.0 or less) Ca19-9 (EIA) 19 (standard value is 37 or less) Ca50 32 (standard value is 40 or less) Before 15 days from operation CEA 16.2 (standard value is 5.0 or less) Ca19-9 (EIA) 128 (standard value is 37 or less) Ca50 96 (standard value is 40 or less)
  • the size was 11 ⁇ 6 cm around 3 ⁇ 4 of transverse colon, being Stage 4.
  • a cancer was metastasized to mesentery lymph gland S-shape colon and the like.
  • the body weight at a normal time was 70 kg, while the body weight was decreased to 49 kg after operation. Cancer markers were all ( ⁇ ). Anemia was observed.
  • Vitamin C Celanese, and Luvox (25) were initiated 5 days after operation.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • Example 1 In principle, the same as Example 1.
  • the present invention exerts such an effect that almost all diseases can be treated by a simple combination of two or more kinds of drugs which have been previously used.
  • the present invention can exert the maximum therapeutic effect while loss of bodily strength of a patient is extremely suppressed, and can avoid an unexpected side effect.
  • the present invention has large applicability in drug industries such as production of drugs for realizing the aforementioned therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/295,139 2006-03-29 2006-07-21 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical Abandoned US20110092548A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-091370 2006-03-29
JP2006091370A JP4615470B2 (ja) 2006-03-29 2006-03-29 大脳の認知力を用いた疾患治療・予防の方法および医薬
PCT/JP2006/314530 WO2007110977A1 (ja) 2006-03-29 2006-07-21 大脳の認知力を用いた疾患治療・予防の方法および医薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314530 A-371-Of-International WO2007110977A1 (ja) 2006-03-29 2006-07-21 大脳の認知力を用いた疾患治療・予防の方法および医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/788,358 Continuation US9579312B2 (en) 2006-03-29 2015-06-30 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical

Publications (1)

Publication Number Publication Date
US20110092548A1 true US20110092548A1 (en) 2011-04-21

Family

ID=38540917

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/295,139 Abandoned US20110092548A1 (en) 2006-03-29 2006-07-21 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
US14/788,358 Active US9579312B2 (en) 2006-03-29 2015-06-30 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/788,358 Active US9579312B2 (en) 2006-03-29 2015-06-30 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical

Country Status (5)

Country Link
US (2) US20110092548A1 (ja)
EP (1) EP2005956B1 (ja)
JP (1) JP4615470B2 (ja)
HK (1) HK1126659A1 (ja)
WO (1) WO2007110977A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579312B2 (en) 2006-03-29 2017-02-28 System C Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
US20180341749A1 (en) * 2017-05-28 2018-11-29 Adriana Monica Druma System and method for interactively displaying directions for use for a product
US11344529B2 (en) 2017-12-07 2022-05-31 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722578C (en) * 2008-05-14 2014-02-11 Sbi Alapromo Co., Ltd. Use of .delta.-amino levulinic acid to treat male infertility

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020103A (en) * 1975-12-24 1977-04-26 Diamond Shamrock Corporation Recovery of calcium pantothenate
US4085225A (en) * 1975-03-20 1978-04-18 U.S. Philips Corporation Oxime ethers having anti-depressive activity
US5089276A (en) * 1989-04-19 1992-02-18 Takeda Chemical Industries, Ltd. Calcium pantothenate composite
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US5837701A (en) * 1995-02-10 1998-11-17 Eduardo Samuel Bleiweiss Composition and method for treating conditions associated with symptoms of unspecified retarded maturation
US6433225B1 (en) * 1999-11-12 2002-08-13 Sun Pharamaceutical Industries, Ltd. Process for the preparation of fluvoxazmine maleate
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US6743953B2 (en) * 2002-08-26 2004-06-01 Kancor Flavours & Extracts Ltd. Process for the preparation of xanthophyll crystals
US20080096926A1 (en) * 2002-10-22 2008-04-24 Drugabuse Sciences Sas Treatment Of Cognitive Impairment Using A Selective Dopamine D1 Receptor Agonist
US7611872B2 (en) * 2001-02-21 2009-11-03 Basf Aktiengesellschaft Method for the production of D-pantothenic acid and/or salts thereof via purification by nanofiltration as adjunct for animal feedstuffs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0220666A (ja) 1988-07-06 1990-01-24 Matsushita Electric Ind Co Ltd 溶接用トーチ
US5292774A (en) 1988-07-26 1994-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substitution fluid preparation comprising 3-hydroxy-butyric acid (β-hydroxybutric acid) and its salts
JPH06312923A (ja) * 1993-04-30 1994-11-08 Green Cross Corp:The 末梢静脈投与用栄養輸液
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6262111B1 (en) * 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
CN1196436C (zh) 1999-08-26 2005-04-13 诺瓦提斯公司 眼分析物传感器
AU2002212970B2 (en) 2000-09-15 2007-05-31 The Scripps Research Institute Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
JP4615470B2 (ja) 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085225A (en) * 1975-03-20 1978-04-18 U.S. Philips Corporation Oxime ethers having anti-depressive activity
US4020103A (en) * 1975-12-24 1977-04-26 Diamond Shamrock Corporation Recovery of calcium pantothenate
US5089276A (en) * 1989-04-19 1992-02-18 Takeda Chemical Industries, Ltd. Calcium pantothenate composite
US5837701A (en) * 1995-02-10 1998-11-17 Eduardo Samuel Bleiweiss Composition and method for treating conditions associated with symptoms of unspecified retarded maturation
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6433225B1 (en) * 1999-11-12 2002-08-13 Sun Pharamaceutical Industries, Ltd. Process for the preparation of fluvoxazmine maleate
US7611872B2 (en) * 2001-02-21 2009-11-03 Basf Aktiengesellschaft Method for the production of D-pantothenic acid and/or salts thereof via purification by nanofiltration as adjunct for animal feedstuffs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US6743953B2 (en) * 2002-08-26 2004-06-01 Kancor Flavours & Extracts Ltd. Process for the preparation of xanthophyll crystals
US20080096926A1 (en) * 2002-10-22 2008-04-24 Drugabuse Sciences Sas Treatment Of Cognitive Impairment Using A Selective Dopamine D1 Receptor Agonist

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cameron et al. (Proc. Natl. Acad. Sci. USA, Vol. 73, No.10, pp.3685-3689, October 1976). *
Cameron et al. (Proc. Natl. Acad. Sci. USA, Vol. 75, No.9, pp.4538-4542), Sept. 1978) *
Marcello De Cisco et al. (Clinical Reviews in Oncology/Hematology 42 (2002) 189-211) *
Masaki Okuyama et al. (Surgery Today (2005) 35:36-40) *
Ross et al. (Am Family Physician 2001;64:807-14, No. 5) *
Weimann et al. (Int J. Vita Nutr Res 1999 Mar, 66(2):113-9) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579312B2 (en) 2006-03-29 2017-02-28 System C Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
US20180341749A1 (en) * 2017-05-28 2018-11-29 Adriana Monica Druma System and method for interactively displaying directions for use for a product
US11344529B2 (en) 2017-12-07 2022-05-31 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions

Also Published As

Publication number Publication date
JP4615470B2 (ja) 2011-01-19
US20150320735A1 (en) 2015-11-12
US9579312B2 (en) 2017-02-28
WO2007110977A1 (ja) 2007-10-04
EP2005956A1 (en) 2008-12-24
JP2007262018A (ja) 2007-10-11
HK1126659A1 (en) 2009-09-11
EP2005956A4 (en) 2012-02-01
EP2005956B1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
JP2961045B2 (ja) 腸管粘膜増強促進剤
US9579312B2 (en) Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
US20080268066A1 (en) Synergistic Formulation for Preventing and/or Treating Diabetes
CN106902104A (zh) 用于治疗神经外伤的方法
CN106456658A (zh) 硒有机化合物的组合物和其使用方法
CN109675041A (zh) 用于治疗癌症的系统、方法和制剂
EA016576B1 (ru) Применение сложных эфиров гидроксибензойной кислоты для получения лекарственного средства для предупреждения и лечения папилломавирусной инфекции человека
JP2010539078A (ja) ジメチルフマレートの新規な用途
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN111346081B (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
WO2013071696A1 (zh) 人体五种正常碱基在制备肿瘤药物中的应用
JP5777011B2 (ja) コルホルシンダロパートを含む骨疾患の予防または治療用組成物
CN101289438A (zh) 3－(3′－羟基)－丁基苯酞酯及其制法和用途
US12128023B2 (en) Pharmaceutical composition containing B-lapachone as active ingredient for prevention or treatment of cholestatic liver disease
JP2018177739A (ja) Ｔｒｐａ１活性化剤
CN118632699A (zh) 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CN107595874A (zh) 一种含有丁苯酞的药物组合物及其在制备治疗脑血管病药物中的应用
US11717013B1 (en) Micronutrient combination to reduce blood pressure
US20230054551A1 (en) Oral pharmaceutical composition and method for delivering nitric oxide to a patient&#39;s circulatory system or brain
RU2490018C1 (ru) Способ терапии гепатозов собак
WO2023155757A1 (zh) 基于菝契皂苷元结构的衍生物及其药物组合物的用途
RU2720134C1 (ru) Фармацевтическая композиция для парентерального капельного введения
JP2024506336A (ja) 膠芽腫の治療方法
KR102470029B1 (ko) 오메가-3 지방산 및 우르소데옥시콜산(udca)을 포함하는 콜레스테롤 담석 예방 또는 치료용 약학적 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION